Iration my insulin every month,” says Khushi Ahuja, a law student from Delhi who has type 1 diabetes and relies on human insulin manufactured by the US company Eli Lilly to manage her condition. While insulin is available at no cost in some public hospitals in India, it is mostly up to individuals to buy the drug.
“Every month I hear about insulin prices rising and I feel guilty about burdening my parents,” Ahuja says. “I skip meals to make my insulin last longer.”
Eli Lilly and two European companies, Novo Nordisk and Sanofi, control 99% of the market by value and 96% of the market by volume. The three manufacturers produce 83% of the insulin sold in low and middle-income countries, where it is now estimated that one in two people who rely on insulin do not have sufficient access to the drug.
Read more at: https://www.theguardian.com/global-development/2023/mar/22/i-skip-meals-to-make-insulin-last-cost-of-diabetes-in-global-south
